Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

CaroGen in pact with NIH to develop flu vaccine

Privately-held CaroGen Corporation has agreed with the National Institute of Allergy and Infectious Diseases, part of the NIH, to provide its AVIDIO-based recombinant influenza vaccine...

| By Kelley Gipson

Vanessa Research secures CE Marking for masks

Vanessa Research has secured the CE Marking, Module C Certificate, for its KLAREX brand KN95 masks. This certification attests to the conformity of the quality of...

| By Kelley Gipson

BI speaks of support for local communities

Yew Looi Liew, President of U.S. Human Pharma at Boehringer-Ingelheim, recently spoke at the Connecticut Bioscience Caucus about the company’s commitment to supporting local communities and...

| By Kelley Gipson

Dr. Nicole Wagner of LambdaVision recognized

WIA (Women in Aerospace) has recognized Dr. Nicole Wagner of LambdaVision for “exceptional leadership, creativity in expanding the boundaries of space-based research, and generous support...

| By Kelley Gipson

Azitra joins team to develop mosquito repellent

Growing Branford biotech Azitra is part of a team working to develop a long-lasting mosquito repellent for the U.S. military using the good bacteria that live...

| By Kelley Gipson

Sema4 and Merus in strategic support agreement

Sema4 reports it has entered into a strategic agreement with Merus, a Dutch company, to utilize Sema4’s advanced genomic testing to identify patients with tumors harboring...

| By Kelley Gipson

Athena Therapeutics closes initial financing round

Athena Therapeutics has closed an initial financing round with HighCape Capital and Connecticut Innovations. Utilizing discoveries and intellectual property licensed from Yale University, Athena plans...

| By Kelley Gipson

BioCT welcomes new member Allyx Therapeutics

Founded in 2019, Allyx Therapeutics is a biotechnology company based in New Haven, CT, developing new therapies to protect synapses from destruction in Alzheimer’s disease...

| By Kelley Gipson

Arvinas raises $400 million in stock offering

Arvinas, a biotechnology company developing two cancer-fighting drugs, recently raised $400 million in a stock offering. After the company released clinical data regarding testing of its...

| By Kelley Gipson

55 Church St in New Haven okayed for lab space

New Haven investor David Goldblum has won city permission to convert an eight-story office building at 55 Church Street into new laboratory an research space. “New Haven...